Nonsurgical treatment of human benign prostatic hyperplasia.
D000726:Androgen Antagonists; D000728:Androgens / Q000627:therapeutic use; D000818:Animals; D002369:Castration; D003534:Cyproterone / Q000627:therapeutic use; D004285:Dogs; D004357:Drug Synergism; D004967:Estrogens / Q000627:therapeutic use; D006728:Hormones / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008524:Medrogestone / Q000627:therapeutic use; D008875:Middle Aged; D011090:Polyenes / Q000627:therapeutic use; D011372:Progestins / Q000627:therapeutic use; D011467:Prostate / Q000473:pathology; D011470:Prostatic Hyperplasia / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D013045:Species Specificity; D013148:Spironolactone / Q000627:therapeutic use
D000726:Androgen Antagonists; D000728:Androgens; D004967:Estrogens; D006728:Hormones; D011090:Polyenes; D011372:Progestins; D008524:Medrogestone; D013148:Spironolactone; D003534:Cyproterone